Oh good you watched it. I was getting a little concerned when you mentioned sending the police around to find someone whom we now know you have heard from recently.
Which customers are you referring to? Were there specific companies? or are you just commenting on the lack of announcements for the execution of new contracts?
I did find the presentation a bit light on too. But I think they are wise to remain committed to satipharm, there is a lot of potential there. Shame about the sleep product - placebo is a powerful thing difficult to gauge how much influence it will have without running the trial ($$$). It will be interesting to see the outcomes of similar trials being conducted by other companies to see if it is a broader issue with cannabis in general or an issue with satipharm or the targeted ailment itself. CAN have promoted the efficacy of satipharm at length and passed efficacy trials recently so its interesting for sure.
Looking forward to hearing about the release of other products they are working on using the satipharm platform, though I suspect for now they are out of the race for OTC sales. At least until they can resolve the trial issues or manage their finances to recommence further trials, which fans of other MC companies take great joy in reminding us. Very helpful commentary for sure!
CAN Price at posting:
14.3¢ Sentiment: Buy Disclosure: Held
